









Markets
/
Stocks
/
nasdaq-alms
/

Alumis Inc

ALMS

26.190USD

-0.150-0.57%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.73BMarket Cap

LossP/E TTM



Alumis Inc

26.190

-0.150-0.57%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alumis Inc

Currency: USD Updated: 2026-02-06

Key Insights

Alumis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 35.57.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alumis Inc's Score

Industry at a Glance

Industry Ranking

56 / 392

Overall Ranking

175 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Alumis Inc Highlights

StrengthsRisks

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -7.16, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 79.11M shares, increasing 1.13% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 21.49K shares of this stock.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

35.571

Target Price

+35.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Alumis Inc is 5.79, ranking 324 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.79

Change



Financials

7.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.48

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alumis Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Alumis Inc is 7.74, ranking 85 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.16, which is -93.76% below the recent high of -0.45 and -5.80% above the recent low of -7.57.

Score

Industry at a Glance

Previous score

7.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Alumis Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 25.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

35.571

Target Price

+35.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Alumis Inc

ALMS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Alumis Inc is 9.44, ranking 10 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 30.29 and the support level at 20.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.52

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.927

Neutral

RSI(14)

64.747

Neutral

STOCH(KDJ)(9,3,3)

54.543

Neutral

ATR(14)

2.053

Low Volatility

CCI(14)

58.984

Neutral

Williams %R

41.096

Buy

TRIX(12,20)

2.549

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

26.468

Sell

MA10

26.371

Sell

MA20

25.119

Buy

MA50

16.503

Buy

MA100

10.639

Buy

MA200

7.352

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Alumis Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 81.97%, representing a quarter-over-quarter decrease of 0.33%. The largest institutional shareholder is The Vanguard, holding a total of 4.10M shares, representing 3.36% of shares outstanding, with 69.46% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Foresite Capital Management, LLC

10.61M

+5.79%

Ayur Maya Capital Management Company, L.P.

15.14M

-0.00%

Samsara BioCapital, LLC

5.13M

+6.95%

VenBio Partners LLC

4.62M

The Vanguard Group, Inc.

Star Investors

4.03M

+18.37%

BlackRock Institutional Trust Company, N.A.

3.79M

-0.46%

Nextech Invest, Ltd.

2.92M

Cormorant Asset Management, LP

2.15M

SR One Capital Management, LP

1.96M

OrbiMed Advisors, LLC

1.93M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alumis Inc is 1.69, ranking 292 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.